Category Archives: Drugs

TRENTON, N.J. (AP) -- Merck & Co., the world's third-biggest drugmaker by revenue, will tout a big surge in the company's pipeline of experimental drugs and a couple of promising new partnerships when it reports first-quarter results before the stock market opens Wednesday. WHAT TO WATCH FOR: CEO Kenneth Frazier will note the company has five new medicines under review by regulators, another just submitted and four others slated to be submitted for review sometime this year. In addition, the Food and Drug Administration this month gave Merck's experimental cancer drug lambrolizumab a "breakthrough therapy" designation. That's meant to hasten final testing and the review process. The drugs currently under regulatory review include insomnia pill suvorexant, ovarian cancer drug vintafolide and sugammadex for reversing effects of anesthesia after surgery. The others are a grass-allergy immunotherapy that gradually reduces allergic reactions and a cholesterol pill combining a generic version of Pfizer Inc.'s former blockbuster Lipitor the top-selling drug in history with Zetia, a Merck pill that controls cholesterol in a different way. Just Monday, Merck and longtime rival Pfizer announced a partnership for further testing and development of Pfizer's experimental Type 2 diabetes pill ertugliflozin. It's about to enter late-stage patient … Continue reading →

By Toni Clarke WASHINGTON (Reuters) - Gilead Sciences Inc said on Monday that U.S. health rejected two of its HIV drugs as standalone therapies, citing deficiencies in documentation and validation of certain quality testing procedures. Gilead said it is working with U.S. Food and Drug Administration to address the questions raised in the rejection letter in order to prove the application forward. The company is seeking approval for its drug elvitegravir for people with HIV, the virus that causes AIDS, who have already been treated with other products. The drug blocks the enzyme integrase which is needed for the HIV virus to replicate. Gilead is also seeking approval of cobicistat, a drug that does not itself fight the virus but boosts the function of other HIV medicines. Both drugs are already contained in Gilead's once-daily single-tablet HIV treatment Stribild, which combines four different medications and was approved in the United States last August. Analysts on average expect elvitegravir, if eventually approved, to generate annual sales of about $300 million by 2016 according to Thomson Reuters data. They expect sales of cobicistat of roughly $242 million over the same period. Overall, Gilead's portfolio of antiviral drugs generated sales in 2012 of … Continue reading →

Doctors argue that some drug companies are charging too much for their cancer drugs, to the detriment of patients. A group of more than 100 cancer experts have called out drug companies for the high prices of cancer drugs. The doctors, all specialists in chronic myelogenous leukemia or CML, published their opinion on what they call astronomical prices on Friday in the scientific journal Blood. They write: [We] believe the current prices of CML drugs are too high, unsustainable, may compromise access of needy patients to highly effective therapy, and are harmful to the sustainability of our national healthcare systems. These reflect the spiraling prices of cancer drugs in general. Of the 12 drugs approved by the FDA for various cancer indications in 2012, 11 were priced above $100,000 per year. Cancer drug prices have almost doubled from a decade ago, from an average of $5,000 per month to more than $10,000 per month. The authors do acknowledge the need for pharmaceutical companies to be rewarded for innovation and discoveries and that the cost of bringing a new cancer drug to market is around $1 billion. But the authors also suggest that current pricing, at least of some drugs, is … Continue reading →

By Barbara Bronson Gray HealthDay Reporter MONDAY, April 29 (HealthDay News) -- People with severe or frequent migraines often turn to drugs to prevent them. But do the medications work? A new review of preventive treatments shows there is not much difference in the effectiveness of commonly prescribed drugs -- they work for some people, in some cases. But there is wide variation in the amount and severity of side effects associated with the drugs. The researchers found that drugs worked better than inactive placebos in reducing monthly migraine attacks. They prevented half or more migraines in 200 to 400 people per 1,000 treated. But many of the medications had side effects so bothersome that sufferers frequently stopped taking them. That could be because none of the drugs used to prevent migraines was designed specifically for that purpose, explained Dr. Jason Rosenberg, director of the Johns Hopkins Headache Center. "So, it's not surprising that they don't work all that well. Only one-third get halfway better, according to the study, so a doctor has to treat three people to get one patient better." Rosenberg, who was not involved with the study, suffers from migraines and thinks many primary care doctors may … Continue reading →

Drugs that block estrogen may lower women's risk of breast cancer for 10 years, according to a new review of studies. Postmenopausal women in the studies who took drugs called selective estrogen receptor modulators (SERMs), such as tamoxifen, were 38 percent less likely to develop any type of breast cancer over a 10-year period, compared with women who werent taking SERMs. The studies also involved the SERMs raloxifene, arzoxifene and lasofoxifene. The review shows that "each of these drugs will prevent breast cancer in populations of women," said Dr. V. Craig Jordan, scientific director of oncology at the Lombardi Comprehensive Cancer Center at Georgetown University. The review "places into perspective the 40-year journey" of SERM research, said Jordan, whose studies in the 1970s showed that tamoxifen prevented mammary cancer in rats. He was not involved in the new study. Only tamoxifen and raloxifene are approved by the Food and Drug Administration for the prevention of breast cancer, and only tamoxifen is approved for use in premenopausal women who are at high risk for breast cancer. The other drugs in the studies are currently being studied as treatments for osteoporosis, but they also lower the risk of breast cancer, Jordan said. … Continue reading →

NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Ophthalmic Drugs: World Market Prospects 2013-2023 http://www.reportlinker.com/p0847305/Ophthalmic-Drugs-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Report Details How to find trends and revenue predictions for the ophthalmic drug industry What are the commercial prospects for treating eye disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for ocular drugs. Our study lets you assess sales data at overall world market, submarket and national level. There you find that industry's most promising and lucrative segments, helping your research and analyses. Therapies for treating eye disorders and diseases have rising demand. See the future of ophthalmic medicines and discover how sales of ocular drugs can increase. Forecasts and other analyses to help you stay ahead in knowledge In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), business outlooks and research and development (R&D). You receive 48 tables, 74 charts and 9 interviews. Read more: Ophthalmic Drugs: World Market Prospects 2013-2023 … Continue reading →

NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Dermatological Drugs: World Market Prospects 2013-2023 http://www.reportlinker.com/p0788690/Dermatological-Drugs-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Report Details Your guide to revenue prospects for the treatment of skin diseases What's the commercial outlook for treating skin disorders? Visiongain's updated report gives you forecasted revenues to 2023 and also explains R&D trends, outlooks and opportunities. Our study lets you assess sales data for the world market, therapeutic submarkets, products and national markets. It shows you that industry's most promising and lucrative segments. Forecasts and other analyses to help you stay ahead in knowledge The report gives you revenue forecasts to 2023, historical data, growth rates and market shares. Also, it lets you see qualitative analysis (SWOT and STEP), business outlooks and developmental trends (R&D). You gain 99 tables, 61 charts and two research interviews. Is finding commercial details a challenge? Our report helps you get ahead in knowledge, benefiting your research, analyses and decisions. Find trends, innovations and opportunities. You see what's happening. There's rising demand for dermal medicines. Discover areas of the market that will prosper, reducing the risk of your being left behind. Read more: Dermatological Drugs: World … Continue reading →

NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Antibacterial Drugs: World Market Prospects 2013-2023 http://www.reportlinker.com/p0739371/Antibacterial-Drugs-World-Market-Prospects-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Report Details Discover new trends, opportunities and revenue prospects for bacteria-killing medicines Where's the antibiotics market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities. Our study lets you assess sales data and predictions for the world antibacterial drugs market, therapeutic submarkets, important products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments. Established and emerging bacteria-treating technologies have potential. Read on to scan features of that industry, find what drives it, and see what its future market could be worth. Forecasts and other analyses to help you stay ahead in knowledge That report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developmental trends (R&D). You gain 113 tables, 86 charts and two research interviews. Is finding commercial data a challenge? With our study you can stay ahead in knowledge, benefiting your research, analyses and … Continue reading →

Ummm....Went to walmart today This is why you dont do drugs. By: virxkiller … Continue reading →

TuRn MuSiC, tUrN oFf DrUgS song lyric by DONY. By: anz ibo … Continue reading →